# IHH Healthcare (Q0F) Q2 2026 earnings

Results filed 2026-08-27 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/ihh-healthcare/2026-q2/
Press release and documents: https://links.sgx.com/1.0.0/corporate-announcements/C041XU6YZZFQH0CK/488b99eb9ae055435b1a7813303c7405a63a66a91ae11cd1097a01466e1154de
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

IHH Healthcare's Malaysia, Türkiye & Europe and India hospitals drove Q2 growth on higher volumes and more complex cases, while Singapore recovered to 51% occupancy ahead of an expected H2 rebound.

IHH's growth came from more inpatient and daycase patients and a more complex mix of cases. Malaysia grew daycase volumes by double digits. Türkiye & Europe saw strong local and foreign demand even as beds were added at Kartal, Kent and Bayindir hospitals. India gained from the Fortis and Gleneagles integration under a maintenance services agreement. Acquisitions of Bayindir Healthcare, TMI Healthcare and Biruni Labs also added to the business.
Management is steering towards double-digit return on equity by 2028 through country-specific plans and Group-level synergies in cost, systems and operations. Priorities include selective brownfield expansion in Malaysia, faster brownfield expansion in India, and a capital-light approach in Türkiye & Europe. The main tension is Singapore, where recovery depends on lifting volumes with more price-competitive insurer packages, while costs and currency swings add pressure elsewhere.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue (reported) | RM7.0b | up 12% year on year | GAAP |
| PATMI (reported) | RM573m | up 29% year on year | GAAP |
| Core PATMI excluding exceptional items | RM675m | up 30% year on year | non-GAAP |
| Diluted EPS (sen) | 6.48 | up 29% from a year ago | GAAP |
| Diluted EPS excluding exceptional items (sen) | 6.44 | up 36% from a year ago | non-GAAP |
| Operating cash flow (H1 2026) | 2,403 |  |  |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Singapore inpatient occupancy | 51% | up from Q1 lows |
| Singapore margin | 29% |  |
| Healthcare facilities | 190 |  |
| Net gearing | 0.4 times |  |

## Key takeaways

1. **Complex cases and higher volumes powered growth** IHH cited more inpatient and daycase admissions and a more acute case mix across the Group. Research coverage also points to growing demand for specialised and complex care.
2. **Singapore is recovering through insurer packages** Occupancy rose to 51% in Q2 from Q1 lows, and new packages launched with leading insurers. More price-competitive packages are expected in coming months, with recovery guided for H2 2026.
3. **India integration and brownfield expansion continue** The Fortis and Gleneagles India maintenance services agreement is driving integration benefits alongside organic growth. IHH plans to accelerate strategic brownfield expansion to meet demand.
4. **Türkiye & Europe demand is strong and broad** Local and foreign patient demand stayed strong even as beds were added at Kartal, Kent and Bayindir hospitals. Acibadem plans to stay capital-light while keeping market leadership.
5. **Acquisitions widen the network and diagnostics reach** Bayindir Healthcare, TMI Healthcare and Biruni Labs were consolidated, acquired in July 2025, January 2026 and June 2026. The latest two added RM160 million of goodwill, and Biruni Labs deepens the diagnostics footprint.

## Questions

**What drove IHH's growth in Q2 2026?** Higher inpatient and daycase volumes and a more complex case mix, plus price adjustments and acquisitions such as Bayindir Healthcare, TMI Healthcare and Biruni Labs. Malaysia, Türkiye & Europe and India led.
**How is IHH's Singapore business doing?** Occupancy recovered to 51% in Q2 from Q1 lows, and IHH launched new packages with leading insurers. More price-competitive packages are expected in coming months, with recovery guided for H2 2026.
**What are IHH's strategic priorities for 2026?** In Malaysia, growing daycase and medical tourism, strengthening payor partnerships and selective brownfield expansion. In Singapore, payor partnerships and medical tourism from non-traditional markets. In India, deeper Fortis and Gleneagles integration and faster brownfield expansion; Acibadem stays capital-light.
**What acquisitions did IHH consolidate recently?** Bayindir Healthcare in July 2025, TMI Healthcare in January 2026 and Biruni Labs in June 2026. TMI Healthcare and Biruni Labs together added RM160 million of goodwill.
**What is IHH's long-term target?** IHH is targeting double-digit return on equity by 2028 through a multi-year transformation. It says it will use country-specific strategies and Group synergies on cost, systems and operational excellence.

